Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Summit Therapeu ADR (SMMT)

Summit Therapeu ADR (SMMT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,564,725
  • Shares Outstanding, K 701,703
  • Annual Sales, $ 0 K
  • Annual Income, $ -614,930 K
  • 60-Month Beta -1.21
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 33.06
Trade SMMT with:

Options Overview Details

View History
  • Implied Volatility 207.02% ( -12.59%)
  • Historical Volatility 104.86%
  • IV Percentile 92%
  • IV Rank 32.69%
  • IV High 631.33% on 10/26/23
  • IV Low 0.93% on 07/25/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 5
  • Volume Avg (30-Day) 305
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 11,545
  • Open Int (30-Day) 9,715

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.06
  • Number of Estimates 1
  • High Estimate -0.06
  • Low Estimate -0.06
  • Prior Year -0.06
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.25 +8.92%
on 03/22/24
4.64 -23.71%
on 03/28/24
-1.08 (-23.38%)
since 03/15/24
3-Month
3.15 +12.39%
on 01/18/24
5.22 -32.18%
on 03/05/24
+0.08 (+2.31%)
since 01/16/24
52-Week
1.30 +172.31%
on 04/28/23
5.22 -32.18%
on 03/05/24
+1.97 (+125.48%)
since 04/14/23

Most Recent Stories

More News
Why Summit Therapeutics Stock Crushed the Market This Week

The company was a standout in the biotech field, rising by nearly 23% over the period.

SF : 74.35 (-0.04%)
SMMT : 3.54 (-3.15%)
Chart of the Day: Summit Therapeutics Begins to Soar

Caution: This company has had legal issues in the past. It is highly speculative. The Chart of the Day belongs to the oncology company Summit Therapeutics (SMMT) . I found the stock by using Barchart's...

SMMT : 3.54 (-3.15%)
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Summit Therapeutics Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

/PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of...

SMMT : 3.54 (-3.15%)
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Summit Therapeutics Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

/PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of...

SMMT : 3.54 (-3.15%)
Why Shares of Summit Therapeutics Slumped on Tuesday

The company's shares have been falling since it announced earnings late last week.

SMMT : 3.54 (-3.15%)
Why Shares of Summit Therapeutics Soared This Week

Summit Therapeutics advanced its lead therapy into two phase 3 trials to treat non-small cell lung cancer.

SMMT : 3.54 (-3.15%)
Summit Therapeutics Announces Initial Indications for Clinical Trials for Ivonescimab (SMT112)

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it has determined its first two indications in non-small cell lung cancer (NSCLC) in which to...

SMMT : 3.54 (-3.15%)
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Summit Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Summit Therapeutics Inc. (“Summit” or “the Company”) (NASDAQ:...

SMMT : 3.54 (-3.15%)
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Summit Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Summit Therapeutics Inc. (“Summit” or “the Company”) (NASDAQ:...

SMMT : 3.54 (-3.15%)
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2022

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the fourth quarter and year ended December...

SMMT : 3.54 (-3.15%)
EPIX : 7.43 (+1.78%)
PBYI : 5.10 (-4.67%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Summit Therapeutics PLC is engaged in the discovery and development of drug to treat the fatal muscle wasting disease Duchenne Muscular Dystrophy and infections caused by the bacteria C. difficile. Summit Therapeutics PLC is headquartered in Abingdon, the United Kingdom.

See More

Key Turning Points

3rd Resistance Point 3.72
2nd Resistance Point 3.67
1st Resistance Point 3.60
Last Price 3.54
1st Support Level 3.48
2nd Support Level 3.43
3rd Support Level 3.36

See More

52-Week High 5.22
Fibonacci 61.8% 3.72
Last Price 3.54
Fibonacci 50% 3.26
Fibonacci 38.2% 2.80
52-Week Low 1.30

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar